Welcome to our dedicated page for SANUWAVE HEALTH news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on SANUWAVE HEALTH stock.
SANUWAVE Health Inc. is a leading provider of noninvasive, biological response activating devices in regenerative medicine. They focus on repairing and regenerating tissue, musculoskeletal, and vascular structures using their PACE™ technology. With a portfolio of products that activate biologic signaling and angiogenic responses, SANUWAVE helps restore the body's natural healing processes and regeneration. Their products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.Rhea-AI Summary
SNWV - SANUWAVE Health, Inc. to Host Live Conference Call to Present Q3 2023 Financial Results. The leading provider of next-generation wound care products will present their Q3 2023 financial results in a live conference call on November 10, 2023, at 8:00AM (ET). Participants can access the call via telephone or an instant Call me™ link. A replay will be available through November 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
-
News
Rhea-AI Summary
SANUWAVE announces preliminary revenues of $4.7M to $4.9M for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). The combined company expects to receive approximately $13.0 million of gross proceeds at closing. The proposed business combination values the combined company at a pro forma enterprise value of $127.5 million. The transaction is expected to close in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. announces its 2nd quarter 2023 results, reporting a 20% increase in revenue compared to the same period last year. UltraMist® systems sold in Q2 2023 increased to 49 from 28 in Q1. Gross margin as a percentage of revenue increased to 74%. Operating income improved by $4.0 million. Net loss for Q2 2023 was $7.3 million, primarily due to non-cash losses on derivative liabilities. The company anticipates Q3 2023 revenue growth of 15-25%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. will host a conference call on August 11 to present its Q2 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. announces the hiring of Andrew Walko as its new President. Walko brings extensive experience in contract manufacturing, supply chain management, and medical device production.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
News
Rhea-AI Summary
SANUWAVE Health, Inc. announces preliminary revenues of $4.5 million to $4.7 million for Q2 2023, indicating 16-21% growth rate over Q2 2022. The results are consistent with the guidance provided in the Q1 2023 earnings release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.5%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.74%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
FAQ
What is the current stock price of SANUWAVE HEALTH (SNWV)?
The current stock price of SANUWAVE HEALTH (SNWV) is $0.015335 as of September 6, 2024.
What is the market cap of SANUWAVE HEALTH (SNWV)?
The market cap of SANUWAVE HEALTH (SNWV) is approximately 18.8M.
What is SANUWAVE Health Inc. known for?
SANUWAVE specializes in noninvasive, biological response activating devices in the regenerative medicine field for tissue repair and regeneration.
What technology does SANUWAVE use in their products?
SANUWAVE's products are based on PACE™ technology, which activates biologic signaling and angiogenic responses.
In which medical areas does SANUWAVE's portfolio find application?
SANUWAVE's products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.
What is SANUWAVE's financial outlook for the future?
SANUWAVE expects significant revenue growth in 2024, with anticipated revenues over $30 million and a gross margin increase into the mid 70s.
What recent achievement did SANUWAVE announce for Q4 2023?
SANUWAVE announced preliminary revenues of $6.6 million to $6.8 million for Q4 2023, representing a new quarterly revenue record for the Company.
What was the outcome of SANUWAVE's special meeting of stockholders on February 21, 2024?
SANUWAVE stockholders approved the business combination with SEP Acquisition Corp., with 70.5% of all shares eligible to vote participating in the election.
What was SANUWAVE's Q1 2024 revenue performance like?
SANUWAVE announced preliminary revenues of $5.7 million to $5.9 million for Q1 2024, the highest Q1 revenues in company history.
How does SANUWAVE plan to communicate future updates?
SANUWAVE plans to provide business updates via conference calls, with details available on their website for investors to access.
What financial measures does SANUWAVE use to assess its performance?
SANUWAVE uses EBITDA and Adjusted EBITDA to evaluate its operating performance, with a focus on historical and prospective financial performance.
What are SANUWAVE's key areas of research and application for their patented technologies?
SANUWAVE focuses on wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions in applying and researching their patented energy transfer technologies.
SANUWAVE HEALTH INC